N/A N=86 Recovery Time and Affecting Factors in Hemodialysis Patients
Dialysis; Complications · Life Quality
Primary: Post-dialysis Recovery Time — 278.02 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=16 Treatment Modification to Reduce Symptom Burden in Hemodialysis
End Stage Renal Disease
Primary: Number of Participants Recruited, Consented, Randomized and Completed — 51; 16; 16; 16 Participants
N/A N=1,431 Enhancing the Cardiovascular Safety of Hemodialysis Care (Dialysafe)
Kidney Failure · End Stage Renal Disease · Hypotension
Primary: Dialysis Session Stability — 0.202; 0.199; 0.172; 0.182 Proportion of sessions
N/A N=16 Expanded Hemodialysis Versus Online Hemodiafiltration
Dialysis Related Complication · Dialysis Hypotension · Hemodialysis-Induced Symptom
Primary: Medium Molecule Clearance — 53; 59.5 ml/min — p=0.4534
N/A N=32 Mechanisms and Phenotypes of Hypertension in Patients in Chronic Hemodialysis
Arterial Hypertension · Hemodialysis
Primary: Cardiac Output — 3.9; 4.10; 4.6 L/min
Phase 2 N=52 Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension
Intra-dialytic Hypotension
Primary: Efficacy of Mannitol Administration in Reducing the Frequency of Intra-dialytic Hypotension (Decline in Systolic Blood Pressure) During the First Three Hemodialysis…
N/A N=139 Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients
Intra-dialytic Hypotension
Primary: Change in Intra-dialytic Decline in Systolic Blood Pressure — 26; 23 mm Hg
N/A N=15 Cerebral Blood Flow During Hemodialysis
Haemodialysis-induced Symptom
Primary: Change in CBF From Baseline (Before Start of the Hemodialysis Study Session), at 20 Minutes, and at the End of the Hemodialysis Study Session, Measured by [15O]H2OPET-CT…
Phase 4 N=309 20070360 Incident Dialysis
Chronic Kidney Disease · Secondary Hyperparathyroidism
Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001
N/A N=8 Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients
Arrhythmias, Cardiac
Primary: Number of Participants With a Significant Arrhythmia Detected — 0 participants
N/A N=1,075 Quality of Life and Depression in Dialysis Patients
Chronic Kidney Disease Stage 5
Primary: Change of Kidney Disease Quality of Life Short Form 1.3 (KDQOL SF 1.3) Score and Beck Depression Inventory(BDI) Score From Visit 1 Period — 1.22; -1.50; 1.62; 0.46 units…
N/A N=36 Study of HemoCare™ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD
End-Stage Renal Disease
Primary: Primary Safety Endpoint — 16.1; 11.6 Adverse Events per 100 Treatments
N/A N=32 Intradialytic Progressive Resistance Training for Maintenance Haemodialysis Patients
Chronic Kidney Disease
Primary: Muscle Cross Sectional Area — 3.24; -4.62; 4.39; -0.15 cm2 — p=0.30
N/A N=19 Conventional Hemodialysis vs. Short Daily Hemodialysis (6 Days / Week) and Mechanisms of Blood Pressure Control
End Stage Renal Disease
Primary: Mean Systolic Blood Pressure Over the Third Month of Each Treatment Arm — 139; 142 mm Hg
N/A N=70 Hand Reflexology for Fatigue and Anxiety in Hemodialysis Patients
End Stage Kidney Disease (ESRD) · Hemodialysis · Anxiety
Primary: Change in Fatigue Levels as Measured by the Arabic FACIT-Fatigue Scale (FACIT-F) — 24.4; 21.7; 29.5; 21.2 Points on FACIT-Fatigue Scale
N/A N=240 POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study
Hyperkalemia
Primary: Incidence of Pre-dialysis HK After the LIDP in <3K Dialysate Patients — 50; 37 Percent of participants
N/A N=16 Feasibility Study for Heparin-free Hemodialysis With the Dialyzer With Endexo™
Chronic Kidney Diseases · Patient Requiring Heparin Free Dialysis Treatments
Primary: The Primary Endpoint is the Number and Percent (%) of Successful Heparin-free HD Sessions for Each Subject in Each Circuit. — 2.4; 2.9 number of successful HD sessions
N/A N=17 Immuno-nutrition Supplementation in Haemodialysis
Chronic Kidney Disease Requiring Chronic Dialysis
Primary: C Reactive Protein - Marker of Systemic Inflammation — 7.3 mg/L
Phase 4 N=16 Identifying and Treating Depression in Hemodialysis Patients
Depression · Hemodialysis-Induced Symptom
Primary: To Determine the Impact of Directly Observed Weekly Fluoxetine Treatment on Remission of Depression Among Hemodialysis Patients. — 6.6 units on a scale
Phase 4 N=184 Treatment Response in Dialysis Anaemia
Anaemia · Haemodialysis
Primary: Haemoglobin Increase of Greater or Equal to 5g/l Following Receipt of Treatment — 53; 61 Participants
Phase 2 N=12 Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease
Hypertension · End Stage Renal Disease
Primary: Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period — -1.5; -3.7; -0.4 mm Hg
N/A N=31 Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function
Hemodialysis · Kidney Failure, Chronic
Primary: QOL: Kidney Disease Quality of Life (KDQOL36) — 74; 72 score on a scale
N/A N=19 Pilot Study of Nutrition in Maintenance Hemodialysis Patients
End-Stage Renal Disease · Meals · Hemodialysis
Primary: Hypotensive Event Frequency — 18; 13 events
N/A N=274 Theranova Randomized, Controlled, Trial (RCT) in China
Chronic Kidney Failure · Acute Kidney Failure
Primary: Reduction Ratio (RR) of Lambda Free Light Chains (λ FLC) — 36.02; 19.03 Reduction Ratio (%) — p=<0.0001
N/A N=13 Comparison Study of Daily Ultrafiltration and Twice-weekly Hemodialysis
End-stage Renal Disease
Primary: Mean Arterial Blood Pressure — 110; 95; 106 mm Hg
N/A N=172 Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients
End Stage Renal Disease
Primary: Reduction Ratio of Lambda Immunoglobulin FLC at Week 24 — 32.156; 17.514 percentage ratio
N/A N=179 Intervention to Reduce Dietary Sodium in Hemodialysis
Renal Dialysis
Primary: Time Specific Interdialytic Weight Gain (Baseline) — 1.2; 1.2 kg/day
N/A N=8 Sodium Chloride and Protein-Bound Toxin Removal in Hemodiafiltration
End-stage Renal Disease
Primary: Removal of Para-cresylsulfate — 42.0; 32.6; 33.6 percentage of reduction
N/A N=96 Impact of Vitamin D Repletion in Hemodialysis Patients
Vitamin D Deficiency · End-stage Renal Disease
Primary: Change in 25OH-Vitamin D Level — 15.8; 40.9 ng/dL
N/A N=56 Effect of Chewing Gum in Hemodialysis Patients
Chewing Gum · Hemodialysis
Primary: Change From Baseline Intradialytic Weight Gain — 2.53; 2.44 kg